732.87

0.62% -4.58

Regeneron Pharmaceuticals Inc (REGN)

Overview News Price History Option Chain Financials Why REGN Down? Discussions Forecast

Regeneron Pharmaceuticals Inc stock is traded at $732.87, with a volume of 1.36M. It is down -0.62% in the last 24 hours and down -6.00% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Previous Close:

$737.45

Open:

$738.17

24h Volume:

1.36M

Relative Volume:

1.75

Market Cap:

$77.48B

Revenue:

$14.34B

Net Income/Loss:

$4.50B

P/E Ratio:

17.63

EPS:

41.5626

Net Cash Flow:

$3.77B

1W Performance:

-1.73%

1M Performance:

-6.00%

6M Performance:

+23.80%

1Y Performance:

+10.60%

1-Day Range:

$728.64

$744.85

1-Week Range:

$727.88

$771.23

52-Week Range:

$476.49

$821.11

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name

Regeneron Pharmaceuticals Inc

Sector

Healthcare (1110)

Industry

Biotechnology (621)

Phone

(914) 847-7000

Address

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Employee

15,410

Twitter

@regeneron

Next Earnings Date

2026-01-30

Latest SEC Filings

REGN's Discussions on Twitter

Compare REGN vs VRTX, ALNY, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REGN Regeneron Pharmaceuticals Inc	732.87	77.48B	14.34B	4.50B	3.77B	41.56
VRTX Vertex Pharmaceuticals Inc	454.00	115.33B	12.07B	3.95B	3.19B	15.33
ALNY Alnylam Pharmaceuticals Inc	312.17	41.40B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	663.93	41.09B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	275.28	30.56B	5.36B	287.73M	924.18M	2.5229

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-06-26	Initiated	Barclays	Overweight
Jan-07-26	Upgrade	BofA Securities	Underperform → Buy
Dec-03-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-24-25	Initiated	HSBC Securities	Buy
Nov-24-25	Resumed	Truist	Buy
Nov-13-25	Initiated	Scotiabank	Sector Perform
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight
May-14-25	Upgrade	Citigroup	Neutral → Buy
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform
Jan-16-25	Downgrade	UBS	Buy → Neutral
Dec-10-24	Resumed	BofA Securities	Underperform
Nov-15-24	Initiated	Wolfe Research	Outperform
Nov-14-24	Initiated	Citigroup	Neutral
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-12-24	Initiated	Bernstein	Outperform
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-09-23	Initiated	Deutsche Bank	Hold
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy
Aug-21-23	Reiterated	Oppenheimer	Perform
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform
Mar-24-23	Upgrade	Jefferies	Hold → Buy
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight
Oct-26-22	Downgrade	Raymond James	Mkt Perform → Underperform
Oct-17-22	Downgrade	Evercore ISI	Outperform → In-line
Sep-09-22	Upgrade	Jefferies	Underperform → Hold
Sep-09-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-25-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-06-22	Initiated	Jefferies	Underperform
May-23-22	Initiated	SVB Leerink	Outperform
Jan-05-22	Downgrade	BofA Securities	Neutral → Underperform
Jan-03-22	Upgrade	Bernstein	Mkt Perform → Outperform
Dec-15-21	Downgrade	Bernstein	Outperform → Mkt Perform
Dec-09-21	Resumed	Wells Fargo	Overweight
Dec-07-21	Resumed	Cowen	Market Perform
Dec-06-21	Initiated	Goldman	Buy
Nov-19-21	Resumed	BMO Capital Markets	Outperform
Nov-05-21	Downgrade	The Benchmark Company	Buy → Hold
Jun-29-21	Initiated	H.C. Wainwright	Buy
Jan-25-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-13-21	Upgrade	The Benchmark Company	Hold → Buy
Jan-08-21	Upgrade	Citigroup	Neutral → Buy
Oct-05-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Aug-20-20	Downgrade	The Benchmark Company	Buy → Hold
Jul-09-20	Upgrade	SunTrust	Hold → Buy
May-26-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Apr-28-20	Downgrade	Citigroup	Buy → Neutral
Apr-17-20	Upgrade	The Benchmark Company	Hold → Buy
Apr-08-20	Initiated	The Benchmark Company	Hold
Mar-31-20	Initiated	Wolfe Research	Peer Perform
Feb-27-20	Initiated	Barclays	Overweight
Feb-26-20	Upgrade	Canaccord Genuity	Hold → Buy
Feb-26-20	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-25-20	Upgrade	Jefferies	Hold → Buy
Feb-11-20	Upgrade	Argus	Hold → Buy
Dec-24-19	Initiated	Raymond James	Mkt Perform
Dec-16-19	Downgrade	Evercore ISI	Outperform → In-line
Dec-13-19	Upgrade	Credit Suisse	Neutral → Outperform
Nov-12-19	Initiated	SunTrust	Hold
Nov-07-19	Upgrade	Citigroup	Neutral → Buy
Oct-17-19	Resumed	BofA/Merrill	Neutral
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy

View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

Mar 21, 2026

Why Regeneron Pharmaceuticals (REGN) is one of the top gene therapy stocks to buy according to hedge funds - MSN

Mar 21, 2026

Analysts Offer Insights on Healthcare Companies: Electrocore (ECOR) and Regeneron (REGN) - The Globe and Mail

Mar 21, 2026

Union Bancaire Privee UBP SA Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 21, 2026

Is It Time To Revisit Regeneron (REGN) After Recent Share Price Pullback? - simplywall.st

Mar 21, 2026

Swiss Life Asset Management Ltd Grows Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 21, 2026

Mar 20, 2026

BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $860 - Moomoo

Mar 20, 2026

PCSK9 Inhibitor Market to Reach US$7.67 Billion by 2033 at 16.5% - openPR.com

Mar 20, 2026

Mar 19, 2026

Atopic Dermatitis Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie - Barchart.com

Mar 19, 2026

Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead? - The Globe and Mail

Mar 19, 2026

Formycon secures license date for aflibercept biosimilar FYB203 in Europe - The Pharma Letter

Mar 19, 2026

Hudson Bay Capital Management LP Sells 31,367 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 19, 2026

Groupama Asset Managment Sells 5,169 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 19, 2026

Mar 18, 2026

Lower LDL Is Better In New ACC/AHA Guidelines, Making The Case For Add-Ons To Statins - Citeline News & Insights

Mar 18, 2026

Trading Action: What are the future prospects of Regeneron Pharmaceuticals Inc2026 Volume Leaders & AI Driven Stock Reports - baoquankhu1.vn

Mar 18, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Mar 18, 2026

Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed On Friday - MSN

Mar 18, 2026

Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN

Mar 18, 2026

Is Regeneron Pharmaceuticals (REGN) One of the Best Gene-Editing Stocks to Buy According to Hedge Funds? - MSN

Mar 18, 2026

Here’s what analysts are saying about Regeneron Pharmaceuticals (REGN) - MSN

Mar 18, 2026

Caerus Investment Advisors LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 18, 2026

Mar 17, 2026

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.

Mar 17, 2026

BAYRY Reports Positive Data on Kidney Drug in Non-Diabetic CKD - The Globe and Mail

Mar 17, 2026

Regeneron: EPS Set to Jump 18% in 2027 as Obesity Bet Reframes the Investment Case - TIKR.com

Mar 17, 2026

Holocene Advisors LP Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 17, 2026

Brevan Howard Capital Management LP Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 17, 2026

California Public Employees Retirement System Sells 111,602 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 17, 2026

Boothbay Fund Management LLC Buys 1,541 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 17, 2026

Mar 16, 2026

Behavioral Patterns of REGN and Institutional Flows - Stock Traders Daily

Mar 16, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Mar 16, 2026

Regeneron and Sanofi Extend Phase 3 Itepekimab Program in Chronic Sinus Disease - TipRanks

Mar 16, 2026

Hamilton Wealth LLC Acquires New Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 16, 2026

Gotham Asset Management LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 16, 2026